Upregulation do HER2 após terapia endócrina neoadjuvante no câncer de mama HR+/HER2-negativo e sobrevida em 5 Anos no estudo WSG-ADAPT-TP

Notas do episódio

Referências: Chaudhary LN, Jorns J, Sun Y, Cheng YC, Kamaraju S, Burfeind J, Gonyo M, Kong A, Patten C, Yen T, Cortina C, Carson E, Johnson N, Bergom C, Tsaih SW, Banerjee A, Wang Y, Chervoneva I, Weil E, Chitambar CR, Rui H. Frequent Upregulation Of HER2 Protein In Hormone Receptor-Positive HER2-Negative Breast Cancer After Short-Term Neoadjuvant Endocrine Therapy. Res Sq [Preprint]. 2023 Apr 7:rs.3.rs-2777910. doi: 10.21203/rs.3.rs-2777910/v1. Update in: Breast Cancer Res Treat. 2023 Jul 17;: PMID: 37066270; PMCID: PMC10104267. https://www.researchsquare.com/article/rs-2777910/v1 Harbeck N, Nitz UA, Christgen M, Kümmel S, Braun M, Schumacher C, Potenberg J, Tio J, Aktas B, Forstbauer H, Grischke EM, Scheffen I, Malter W, von Schumann R, Just M, Zu Eulenburg C, Biehl C, Kolberg-Liedtke C, Deurloo R, de Haas S, Jóźwiak K, Hauptmann M, Kates R, Graeser M, Wuerstlein R, Kreipe HH, Gluz O; WSG-ADAPT investigators. De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial. J Clin Oncol. 2023 Aug 1;41(22):3796-3804. doi: 10.1200/JCO.22.01816. Epub 2023 Feb 21. PMID: 36809046. https://ascopubs.org/doi/10.1200/JCO.22.01816 --